Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Basilea Pharmaceutica Ltd
Basilea Pharmaceutica Ltd
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Spexis sells preclinical antibiotics programme to Basilea
The CHF 2m deal gives Basilea ownership of a novel programme of Gram-negative bacteria-targeting antibiotics
Finance
Spexis announces sale of preclinical antibiotics programme to Basilea
Basilea to pay up to CHF2m for a preclinical programme with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Research & Development
Forge and Basilea partner on antibiotic discovery
Forge Therapeutics’s platform will be used by Basilea Pharmaceutica to develop inhibitors against two historically difficult-to-drug, unexploited antibiotic targets
Research & Development
Basilea awarded up to US$100m contract from BARDA
To advance clinical Phase III programme for ceftobiprole antibiotic
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Latest EU drug approvals span range of health issues
Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Research & Development
Basilea's Chief Technology Officer to retire
Dr Günter Ditzinger named as successor Dr Ingrid Heinze-Krauss
Research & Development
Consortium signs deal with Basilea to develop targeted cancer therapy
Clinical Phase I testing of panRAF kinase inhibitors is expected to start this year
Subscribe now